未经批准:对于几种癌症,包括乳房,诊断时年龄小与不良预后相关.虽然这种效应通常归因于可遗传的突变,如BRCA1/2,病理特征之间的关系,年轻的发病年龄,乳腺癌的预后仍不清楚。在本研究中,我们强调了美国女性乳腺癌患者的发病年龄和淋巴结转移(NM)之间的联系.
UNASSIGNED:来自监视的案例列表,流行病学,和最终结果(SEER)18乳腺癌妇女的登记数据,其中包括关于种族的信息,被使用。对具有受体亚型信息的女性子集的NM及其相关结果进行评估,然后与更大的女性进行比较,来自同一注册表的pre-subtype验证数据集。诊断年龄是5类变量;40岁以下,40-49岁,50-59岁,60-69岁和70岁以上。将单变量和调整后的多变量生存模型应用于两组数据。
未经评估:根据调整后的逻辑回归模型确定,诊断时40岁以下的女性患NM的几率是60~69岁女性的1.55倍.(HR=激素受体)HR+/HER2+的NM几率,HR-/HER2+,三阴性乳腺癌亚型明显低于HR+/HER2-。在子类型分层调整模型中,诊断年龄有一致的趋势,即按年龄分类NM的几率下降,最明显的是HR+管腔A和B亚型。按年龄划分的单变量5年生存率对于40岁以下的女性来说是最差的,在调整后的多变量模型中,NM占癌症死亡风险的49%。
未经证实:淋巴结转移与年龄有关,然而,并非所有的分子亚型都明显受到这种关系的影响。对于<40岁的女性,NM是缩短生存期的主要原因。当按亚型分层时,最强的关联是HR+组,提示年轻的乳腺癌发病和NM之间可能存在激素联系。
UNASSIGNED: For several cancers, including those of the breast, young age at diagnosis is associated with an adverse prognosis. Although this effect is often attributed to heritable mutations such as BRCA1/2, the relationship between pathologic features, young age of onset, and prognosis for breast cancer remains unclear. In the present study, we highlight links between age of onset and lymph node metastasis (NM) in US women with breast cancer.
UNASSIGNED: Case listings from Surveillance, Epidemiology, and End Result (SEER) 18 registry data for women with breast cancer, which include information on race, were used. NM and its associated outcomes were evaluated for a subset of women with receptor subtype information and then compared against a larger, pre-subtype validation set of data from the same registry. Age of diagnosis was a 5-category variable; under 40 years, 40-49 years, 50-59 years, 60-69 years and 70+ years. Univariate and adjusted multivariate survival models were applied to both sets of data.
UNASSIGNED: As determined with adjusted logistic regression models, women under 40 years old at diagnosis had 1.55 times the odds of NM as women 60-69 years of age. The odds of NM for (HR = hormone receptor) HR+/HER2+, HR-/HER2+, and triple-negative breast cancer subtypes were significantly lower than those for HR+/HER2-. In subtype-stratified adjusted models, age of diagnosis had a consistent trend of decreasing odds of NM by age category, most noticeable for HR+ subtypes of luminal A and B. Univariate 5-year survival by age was worst for women under 40 years, with NM attributable for 49% of the hazard of death from cancer in adjusted multivariate models.
UNASSIGNED: Lymph node metastasis is age-dependent, yet not all molecular subtypes are clearly affected by this relationship. For <40-yr-old women, NM is a major cause for shorter survival. When stratified by subtype, the strongest associations were in HR+ groups, suggesting a possible hormonal connection between young age of breast cancer onset and NM.